VKH
MDGL icon

Virtu KCG Holdings’s Madrigal Pharmaceuticals MDGL Stock Holding History

Virtu KCG Holdings’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,219
Closed -$11K – 3304
2016
Q2 		$11K Sell
1,219
-1,840
-60% -$22.1K ﹤0.01% 2839
2016
Q1 		$26K Sell
3,059
-2,290
-43% -$19.1K ﹤0.01% 2565
2015
Q4 		$66K Buy
+5,349
New +$147K ﹤0.01% 3103
2015
Q3 		– Sell
-1,559
Closed -$122K – 3641
2015
Q2 		$122K Sell
1,559
-922
-37% -$77.4K ﹤0.01% 2840
2015
Q1 		$168K Buy
2,481
+1,267
+104% +$109K ﹤0.01% 2480
2014
Q4 		$113K Sell
1,214
-1,334
-52% -$138K ﹤0.01% 3166
2014
Q3 		$268K Buy
2,548
+1,252
+97% +$174K 0.01% 2511
2014
Q2 		$185K Buy
1,296
+710
+121% +$104K ﹤0.01% 3100
2014
Q1 		$88K Buy
+586
New +$115K ﹤0.01% 3234
2013
Q4 		– Sell
-380
Closed -$84K – 4064
2013
Q3 		$84K Buy
+380
New +$80.8K ﹤0.01% 3405

Other funds holding MDGL

CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Virtu KCG Holdings's MDGL Position: Q3 2016 in Review

Virtu KCG Holdings sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2016, closing a stake of 1,219 shares — an estimated $11K sold.

Virtu KCG Holdings first reported a position in MDGL in Q3 2013 and held it in 10 quarters. The position peaked at $268K in Q3 2014. 31 funds tracked by Wall St. Rank hold MDGL as of Q3 2016.

  • Virtu KCG Holdings reported no remaining Madrigal Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Virtu KCG Holdings sold 1,219 Madrigal Pharmaceuticals shares in Q3 2016, an estimated $11K.
  • Virtu KCG Holdings first reported a position in Madrigal Pharmaceuticals in Q3 2013 and held it in 10 quarters.
  • Virtu KCG Holdings's Madrigal Pharmaceuticals position peaked at $268K in Q3 2014.
  • 31 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2016.

Based on Virtu KCG Holdings's 13F filing for Q3 2016, filed 10 Nov 2016.